Back to search

University of British Columbia

Phase II 6-month cyclic progesterone/spironolactone pilot therapy trial in polycystic ovary syndrome—a pre-post one-arm feasibility study

Abstract

dc:description

Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly impacts quality of life. Existing treatments often fail to address root causes or meet primary concerns of affected individuals. This study evaluated the feasibility and impact of a 6-month treatment with cyclic progesterone and spironolactone on health-related quality of life in women with androgenic PCOS. Methods: A 6-month open-label, pre-post pilot study was conducted with 26 participants (mean age 29 ± 4.9 years, BMI 30.3 ± 8.1 kg/m², 61.5% White). Within-woman changes assessed using the PCOS-specific quality of life questionnaire (PCOSQ), acne severity, and sleep quality. Demographic, socioeconomic, comorbidities, lifestyle variables, and biochemical measures were analyzed. Results: Significant improvements were observed in the total PCOSQ score, increasing from 3.5 ± 1.0 (95% CI: 3.1; 3.8) at baseline to 4.9 ± 1.1 (95% CI: 4.6; 5.3) at 6 months (t(25) = -6.56, P = .0000007). All domains showed enhancements: emotional well-being (3.5 ± 1.2, 95% CI: 3.0; 3.9, IQR = 1.8) to 5.0 ± 1.4 (95% CI: 4.5; 5.6, IQR = 1.9) (Z = -4.0, P = .000009); body hair concerns (4.0 ± 1.8, 95% CI: 3.2; 4.7, IQR = 3.4) to 5.4 ± 1.4 (95% CI: 4.8; 5.9, IQR = 1.6) (Z = -4.4, P = .00003); weight concerns (2.6 ± 1.8, 95% CI: 1.8; 3.3, IQR = 2.1) to 4.2 ± 2.0 (95% CI: 3.4; 4.5, IQR = 3.6) (Z = -4.1, P = .0001); infertility-related distress (3.9 ± 1.5, 95% CI: 3.3; 4.5, IQR = 1.9) to 5.3 ± 1.4 (95% CI: 4.7; 5.9, IQR = 1.5) (Z = -4.1, P = .00005); and menstrual concerns (3.6 ± 1.1, 95% CI: 3.2; 4.1, IQR = 1.2) to 4.9 ± 1.4 (95% CI: 4.3; 5.4, IQR = 1.5) (Z = -3.5, P = .0009). Perceived acne severity and sleep quality also significantly improved. Conclusions: Cyclic progesterone and spironolactone showed potential as effective treatment options for improving quality of life in women with androgenic PCOS, addressing multiple symptoms. These findings support further research and suggest the need for randomized trials comparing cyclic progesterone/spironolactone to standard-of-care combined hormonal contraception.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Experimental Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Nelson, Kaitlin
Contributors dc:contributor
  • Prior, Jerilynn C., 1943-

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/90057

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Nelson, Kaitlin. Phase II 6-month cyclic progesterone/spironolactone pilot therapy trial in polycystic ovary syndrome—a pre-post one-arm feasibility study. master's thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/90057